Hospital Mater Dei Valuation
Is MATD3 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
3/6Valuation Score 3/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of MATD3 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: MATD3 (R$4.32) is trading below our estimate of fair value (R$9.28)
Significantly Below Fair Value: MATD3 is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for MATD3?
Key metric: As MATD3 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is MATD3's PS Ratio? | |
|---|---|
| PS Ratio | 0.7x |
| Sales | R$2.28b |
| Market Cap | R$1.50b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 1.3x |
| Enterprise Value/EBITDA | -9.2x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does MATD3's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 0.5x | ||
KRSA3 Kora Saúde Participações | 0.2x | 6.5% | R$525.3m |
RDOR3 Rede D'Or São Luiz | 1.3x | 11.6% | R$66.2b |
DASA3 Diagnósticos da América | 0.1x | 6.6% | R$1.8b |
ONCO3 Oncoclínicas do Brasil Serviços Médicos | 0.3x | 11.7% | R$2.0b |
MATD3 Hospital Mater Dei | 0.7x | 6.2% | R$1.5b |
Price-To-Sales vs Peers: MATD3 is expensive based on its Price-To-Sales Ratio (0.7x) compared to the peer average (0.5x).
Price to Sales Ratio vs Industry
How does MATD3's PS Ratio compare vs other companies in the South American Healthcare Industry?
| 3 Companies | Price / Sales | Estimated Growth | Market Cap |
|---|---|---|---|
| 3 Companies | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Sales vs Industry: MATD3 is good value based on its Price-To-Sales Ratio (0.7x) compared to the South American Healthcare industry average (0.8x).
Price to Sales Ratio vs Fair Ratio
What is MATD3's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 0.7x |
| Fair PS Ratio | 0.4x |
Price-To-Sales vs Fair Ratio: MATD3 is expensive based on its Price-To-Sales Ratio (0.7x) compared to the estimated Fair Price-To-Sales Ratio (0.4x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | R$4.32 | R$7.59 +75.7% | 22.1% | R$9.90 | R$5.30 | n/a | 9 |
| Nov ’25 | R$4.07 | R$7.64 +87.8% | 21.1% | R$9.90 | R$5.30 | n/a | 9 |
| Oct ’25 | R$4.42 | R$7.87 +78.0% | 19.6% | R$9.90 | R$5.30 | n/a | 9 |
| Sep ’25 | R$4.66 | R$8.43 +80.8% | 15.4% | R$9.90 | R$6.50 | n/a | 8 |
| Aug ’25 | R$4.59 | R$8.74 +90.4% | 12.3% | R$9.90 | R$6.50 | n/a | 8 |
| Jul ’25 | R$4.55 | R$8.79 +93.1% | 8.0% | R$9.50 | R$7.50 | n/a | 7 |
| Jun ’25 | R$5.02 | R$9.76 +94.4% | 16.1% | R$13.00 | R$8.00 | n/a | 7 |
| May ’25 | R$5.68 | R$9.98 +75.6% | 13.7% | R$13.00 | R$8.80 | n/a | 8 |
| Apr ’25 | R$5.66 | R$9.98 +76.2% | 13.7% | R$13.00 | R$8.80 | n/a | 8 |
| Mar ’25 | R$6.40 | R$9.98 +55.9% | 13.7% | R$13.00 | R$8.80 | n/a | 8 |
| Feb ’25 | R$6.40 | R$10.48 +63.7% | 13.1% | R$13.00 | R$8.80 | n/a | 8 |
| Jan ’25 | R$8.35 | R$10.91 +30.7% | 12.6% | R$13.00 | R$9.00 | n/a | 8 |
| Dec ’24 | R$7.96 | R$10.91 +37.1% | 12.6% | R$13.00 | R$9.00 | n/a | 8 |
| Nov ’24 | R$7.08 | R$10.98 +55.0% | 11.8% | R$13.00 | R$9.00 | R$4.07 | 8 |
| Oct ’24 | R$8.70 | R$11.73 +34.8% | 7.5% | R$13.00 | R$10.50 | R$4.42 | 8 |
| Sep ’24 | R$9.78 | R$11.73 +19.9% | 7.5% | R$13.00 | R$10.50 | R$4.66 | 8 |
| Aug ’24 | R$10.40 | R$11.73 +12.7% | 7.5% | R$13.00 | R$10.50 | R$4.59 | 8 |
| Jul ’24 | R$10.66 | R$11.00 +3.2% | 11.8% | R$13.00 | R$8.50 | R$4.55 | 8 |
| Jun ’24 | R$9.75 | R$11.00 +12.8% | 11.8% | R$13.00 | R$8.50 | R$5.02 | 8 |
| May ’24 | R$8.40 | R$11.19 +33.2% | 11.8% | R$13.00 | R$8.50 | R$5.68 | 8 |
| Apr ’24 | R$7.85 | R$11.19 +42.5% | 11.8% | R$13.00 | R$8.50 | R$5.66 | 8 |
| Mar ’24 | R$8.38 | R$11.31 +35.0% | 12.7% | R$13.00 | R$8.50 | R$6.40 | 8 |
| Feb ’24 | R$9.51 | R$11.19 +17.6% | 12.6% | R$13.00 | R$8.50 | R$6.40 | 8 |
| Jan ’24 | R$7.21 | R$11.81 +63.8% | 10.4% | R$14.00 | R$10.00 | R$8.35 | 8 |
| Dec ’23 | R$7.42 | R$11.94 +60.9% | 10.8% | R$14.00 | R$10.00 | R$7.96 | 8 |
| Nov ’23 | R$9.34 | R$11.94 +27.8% | 10.8% | R$14.00 | R$10.00 | R$7.08 | 8 |
Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.
Discover undervalued companies
Teladoc Health
US$1.8b
Provides virtual healthcare services worldwide.
T2DH34
US$2.38
7D
35.2%
1Y
-15.9%
Qualicorp Consultoria e Corretora de Seguros
R$646.5m
Qualicorp Consultoria e Corretora de Seguros S.A.
QUAL3
R$2.40
7D
2.6%
1Y
-13.0%
Koninklijke Philips
€24.2b
Operates as a health technology company in North America, the Greater China, and internationally.
PHGN34
€152.70
7D
2.0%
1Y
n/a